PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

World Psychiatry

2 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

World Psychiatry has 2 tracked papers indexed in Blossom (2018–2021) from 2 authors, across Depressive Disorders, Anxiety Disorders and Treatment-Resistant Depression (TRD).

Published Papers

Open Accessmeta

The need for publicly funded research on therapeutic use of psychedelic drugs

This perspective paper (2021) advocates the need for public funding of independent evaluations of the efficacy of psychedelic drugs, given that current research efforts spurred by private philanthropic interests may propel a widespread use of psychedelics and demands to implement them as a first-line treatment, ahead of the evidence on their safety, efficacy, and long-term effects.

Published
May 18, 2021
Journal
World Psychiatry
Authors
Hall, W.
Open Accessmeta

Serotonin, psychedelics and psychiatry

This commentary (2018) proposes a theoretical model wherein 5-HT2A receptor stimulation-the primary mechanism of psychedelics-relaxes prior beliefs and heightens sensitivity to context, contrasting with the stabilising role of the 5-HT1A receptor. It suggests that this mechanism facilitates effective therapeutic change by enabling the revision of rigid assumptions and behaviours during periods of uncertainty.

Published
September 7, 2018
Journal
World Psychiatry
Authors
Carhart-Harris, R. L.

Quick Facts

Papers Indexed
2
h-Index
153
Open Access
Yes
Publisher
Wiley
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.